TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26338094
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg Q4W
Study: 26338094
Drug: Patisiran (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran (all doses)
Study: 26341049
Drug: Albuterol overuse
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol overuse (3 or more canisters per year)
Study: 26341049
Drug: Albuterol use
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol use on symptom days (80% or more)
Study: 26341049
Drug: Albuterol use
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol use on symptom-free days (less than 20%)
Study: 26341049
Drug: Controller medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controller medication adherence (80% or more of prescribed doses)
Study: 26341131
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered glucagon at a dose of 2 µg/kg (total mean dose of 1,126 µg over 16 h)
Study: 26341131
Drug: Insulin action
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin action model
Study: 26343101
Drug: Transdermal magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal magnesium chloride solution (4 sprays per limb twice daily for 4 weeks)
Study: 26343348
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy for Arabic children with pain score 7 to 10 (99.05%)
Study: 26343348
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy for Jewish children with pain score 7 to 10 (99.08%)
Study: 26343348
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy for Arabic children approached by Arabic nurses (98.9%)
Study: 26343348
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy for Arabic children approached by Jewish nurses (99%)
Study: 26343348
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy for Jewish children approached by Jewish nurses (98.9%)
Study: 26343348
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy for Jewish children approached by Arab nurses (98.9%)
Study: 26343348
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy for Arabic children during conflict (100%)
Study: 26343348
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy for Jewish children during conflict (96%)
Study: 26348753
Drug: Postnatal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal steroid use
Study: 26349473
Drug: Volasertib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib 300 mg plus afatinib 30 mg (Schedule A)
Study: 26349473
Drug: Volasertib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib 300 mg plus afatinib 70 mg (Schedule B)
Study: 26349473
Drug: Volasertib 150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib 150-300 mg (Schedule A)
Study: 26349473
Drug: Volasertib 150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib 150-300 mg (Schedule B)
Study: 26349821
Drug: Intravenous amoxicillin-clavulanic
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amoxicillin-clavulanic acid (25 to 35 mg/kg of body weight every 6 h)
Study: 26349821
Drug: Monte Carlo
Normalized name: Carbo animalis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monte Carlo simulations for dosing
Study: 26349821
Drug: 1-h infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h infusion for patients with augmented renal function
Study: 26349821
Drug: Current dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current dosing regimens
Study: 29507062
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g every 8 h
Study: 26349823
Drug: Frequent intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent intermittent bolus dosing, extended and continuous infusion
Study: 26349823
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of piperacillin
Study: 26351323
Drug: AKT inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT inhibitor AZD5363
Study: 26351323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AZD5363 and FGFR inhibitor AZD4547
Study: 26351323
Drug: Allosteric AKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allosteric AKT inhibitor MK-2206 and catalytic AKT inhibitor AZD5363
Study: 26351323
Drug: AZD5363 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5363 monotherapy
Study: 26351392
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza vaccine, administered in the years 2009-2010 and 2010-2011.
Study: 26352815
Drug: CTL019 cells
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTL019 cells infusion after myeloablative chemotherapy (melphalan, 140 mg/m²) and autologous stem-cell transplantation
Study: 26352815
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose melphalan (200 mg/m²) followed by autologous transplantation
Study: 26354529
Drug: Serum folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum folate >26.3 ng/mL
Study: 26354529
Drug: Serum vitamin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum vitamin B-12 >701 pg/mL
Study: 26354529
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum concentrations of folate and vitamin B-12 before ART treatment
Study: 26354756
Drug: Successful immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful immunosuppressive therapy
Study: 26355708
Drug: CD34+ peripheral
Normalized name: Autologous peripheral blood-derived CD34+ cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ peripheral blood cells analyzed for del(12p) using sequential fluorescence in situ hybridization (FISH) analyses
Study: 26356834
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of β-blockers in CHART-2 Study
Study: 26358172
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 mcg for 18-24 months)
Study: 26359009
Drug: Daptomycin treatment
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin treatment
Study: 26360334
Drug: Ambrisentan 10
Normalized name: ambrisentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 10 mg and Tadalafil 40 mg daily for 36 weeks
Study: 26362903
Drug: Fingolimod treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod treatment (1d)
Study: 26362903
Drug: Fingolimod treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod treatment (3mo)
Study: 26363899
Drug: Inclacumab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclacumab 0.3 mg/kg
Study: 26363899
Drug: Inclacumab 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclacumab 3.0 mg/kg
Study: 26363899
Drug: Inclacumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclacumab (all doses)
Study: 26364984
Drug: Oral Methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Methadone (0.1 mg/kg per dose every 6 hours)
Study: 26364984
Drug: Optimized dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized dosing strategies based on simulated PK profiles
Study: 26366430
Drug: Maraviroc 600
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 600 mg twice daily
Study: 26370823
Drug: calcium-free balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium-free balanced solution
Study: 26371152
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg once daily and Elbasvir 50 mg once daily coadministered with weight-based Ribavirin twice daily for 12 weeks
Study: 26372452
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) administered within 5 days after onset of illness
Study: 26372452
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) administered after 10 days
Study: 26375437
Drug: Underwater EMR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underwater EMR (UEMR) without submucosal injection
Study: 26375439
Drug: MET tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET tyrosine kinase inhibitors and a monoclonal antibody targeting MET
Study: 26375670
Drug: Rapa (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapa (1 mg) and HCQ (200 mg) twice daily for two weeks
Study: 26375808
Drug: Methylphenidate immediate-release
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate immediate-release (MPH-IR) treatment
Study: 26375845
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC of 5 intravenously every 21 days), Everolimus (5 mg orally once daily), Prednisone (5 mg orally twice daily)
Study: 26375845
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC of 4 for subsequent patients after dose adjustment)
Study: 26375845
Drug: mTOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor everolimus added to carboplatin
Study: 26376459
Drug: IV-Erwinia (25,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-Erwinia (25,000 IU/m²/dose administered on Monday/Wednesday/Friday for 2 consecutive weeks)
Study: 26376939
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day until progression/discontinuation or commercial availability
Study: 27868471
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin monotherapy
Study: 26379163
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) as oral solution or capsule sprinkle plus didanosine and emtricitabine (FTC)
Study: 26379163
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) as capsule sprinkle
Study: 26379282
Drug: Intravenous 5
Normalized name: immune globulin intravenous 5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5 mg/m2 romidepsin once weekly for 3 weeks while maintaining ART
Study: 26379759
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (150 ± 106 mg/day)
Study: 26380086
Drug: ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipilimumab (10 mg/kg IV every 3 weeks, 2 doses)
Study: 26380150
Drug: Ruxolitinib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib with concomitant ESA administration
Study: 26381530
Drug: Everolimus (3mg/m²/day,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (3mg/m²/day, titrated to target blood trough levels of 5-15ng/ml)
Study: 26381736
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg) administered 0.5 hours before cangrelor discontinuation
Study: 26381736
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg) administered 1 hour before cangrelor discontinuation
Study: 26381736
Drug: Clopidogrel administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administered immediately after cangrelor discontinuation
Study: 26385385
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with S-1
Study: 26385462
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor antagonist exendin 9-39 (during infusion)
Study: 26385462
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) infusion
Study: 26386794
Drug: Higher-potency adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-potency adenosine diphosphate receptor inhibitors (prasugrel/ticagrelor)
Study: 26389799
Drug: Benzimidazoles treatment
Normalized name: benzimidazole
DrugBank: Benzimidazole (DB02962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzimidazoles treatment (abrogated after normalization of FDG-PET/CT and anti-EmII/3-10 levels)
Study: 26389799
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group B with continued chemotherapy)
Study: 26389849
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of veltuzumab (80, 160, or 320 mg every 2 weeks × 4 doses)
Study: 26389849
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of veltuzumab (160 or 320 mg twice-weekly × 16 doses)
Study: 26389849
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of veltuzumab
Study: 26390038
Drug: Hu5F9-G4 (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu5F9-G4 (humanized anti-CD47 antibody)
Study: 26390038
Drug: Hu5F9-G4 (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu5F9-G4 (humanized anti-CD47 antibody) + rituximab
Study: 26390837
Drug: COVA322 (bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVA322 (bispecific TNF/IL-17A inhibitor)
Study: 26391354
Drug: Children's reports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's reports of past problems with medication
Study: 26392102
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg daily)
Study: 26392348
Drug: Interferon-beta-1a therapy
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta-1a therapy for nine days
Study: 26392763
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity level (PAL) measured by activity monitor (SenseWear Pro™)
Study: 26393854
Drug: Radiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation with Androgen Deprivation Therapy
Study: 26393854
Drug: Radiation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation without Androgen Deprivation Therapy
Study: 26394198
Drug: A2NTX (low-molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2NTX (low-molecular weight subtype A2 preparation)
Study: 26394202
Drug: Riluzole (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (8 mg/kg) administered 1 hour after injury and every 12 hours thereafter for 7 days at 6 mg/kg
Study: 26395347
Drug: Volasertib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (300 mg once every 3 weeks) + Nintedanib (200 mg twice daily)
Study: 26396157
Drug: Maraviroc (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (300 mg twice a day) plus raltegravir (400 mg twice a day)
Study: 26396720
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones capsules
Study: 26398290
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat challenge
Study: 26400297
Drug: MSCs/HGF (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSCs/HGF (autologous bone marrow MSCs transfected with human HGF cDNA) administered intravenously at a dose of 2 x 10(6) cells/kg, weekly for three consecutive weeks.
Study: 26402159
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy for 3 weeks
Study: 26403509
Drug: LY2090314 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2090314 (40 mg) plus pemetrexed (500 mg/m2) and carboplatin (5-6 AUC) every 21 days
Study: 26403509
Drug: LY2090314 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2090314 monotherapy (≥ 40 mg)
Study: 26403509
Drug: LY2090314 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2090314 (40 mg) plus pemetrexed/carboplatin
Study: 26403509
Drug: LY2090314 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2090314 (40 mg)
Study: 26405584
Drug: DPX-Survivac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPX-Survivac vaccine in combination with metronomic cyclophosphamide
Study: 26405584
Drug: DPX-Survivac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPX-Survivac vaccine
Study: 26405686
Drug: Diazoxide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (0.3 mg/d)
Study: 26405686
Drug: Diazoxide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (4 mg/d)
Study: 26405686
Drug: Diazoxide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (0.3 mg/d) and (4 mg/d)
Study: 26407235
Drug: PF-03084014 (gamma-secretase
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03084014 (gamma-secretase inhibitor)
Study: 26407818
Drug: Ipilimumab (IPI)
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab (IPI) 10 mg/kg plus Dacarbazine (DTIC) 850 mg/m(2) every 3 weeks for four doses (q3w × 4)
Study: 26410176
Drug: Ultra-low-dose combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose combined oral contraceptive (1.0-mg norethindrone acetate and 10-mcg ethinyl estradiol)
Study: 26410424
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg every 3 weeks for four doses
Study: 26413873
Drug: Low-dose IL2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL2 (1x10^6 U/m2 first month, 1.5x10^6 U/m2 following months)
Study: 26413873
Drug: Low-dose IL2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL2
Study: 26413982
Drug: Oxaliplatin 130
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m² on day 1 and prednisone 100 mg/day on days 1-5 of each cycle
Study: 26413982
Drug: Oxaliplatin-prednisone chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin-prednisone chemotherapy
Study: 26415085
Drug: Prenatal exposure
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exposure to maternal cancer with treatment (chemotherapy, radiotherapy, surgery, or other drug treatments)
Study: 26415085
Drug: Prenatal exposure
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exposure to maternal cancer with or without treatment
Study: 26415600
Drug: Drug-Eluting Stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stents (DES) with routine platelet reactivity testing
Study: 26415600
Drug: Premature discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature discontinuation of dual antiplatelet therapy
Study: 26416471
Drug: Telaprevir 750
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 750 mg every 8 h (1125 mg if on efavirenz) plus pegylated interferon-alpha (PEG-IFN, 180 μg once-weekly) and ribavirin (RBV, 800 mg/day) for 12 weeks, followed by 36 weeks of PEG-IFN/RBV
Study: 26416564
Drug: Capecitabine 750
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 750 mg/m² bid, Paclitaxel 60 mg/m²/week, Carboplatin AUC of 6
Study: 26416780
Drug: Prolonged-infusion meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged-infusion meropenem (40 mg/kg every 8 h as a 3 h infusion)
Study: 26416780
Drug: Prolonged-infusion meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged-infusion meropenem
Study: 26416780
Drug: 0.5 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 h infusion
Study: 26417987
Drug: Biomodulatory metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomodulatory metronomic therapy
Study: 26419191
Drug: Cadazolid 3000
Normalized name: Cadazolid
DrugBank: Cadazolid (DB11847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadazolid 3000 mg oral dose
Study: 26419198
Drug: EV71 inactivated
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 inactivated vaccine
Study: 26420017
Drug: Sedation or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation or analgesia (continuous infusion, intermittent doses, or both)